<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975597</url>
  </required_header>
  <id_info>
    <org_study_id>2013.053</org_study_id>
    <nct_id>NCT01975597</nct_id>
  </id_info>
  <brief_title>Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer</brief_title>
  <official_title>Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to demonstrate the team's ability to collect bone marrow
      aspirates and biopsies for research purposes from women with metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of patient that agree to undergo 2 biopsy's strictly for research purposes.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Bone marrow aspirates and biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspirates and biopsy</intervention_name>
    <arm_group_label>Bone marrow aspirates and biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic breast cancer (any site) age 21 or older

          -  Patients willing and able to provide informed consent &amp; perform study procedures

          -  Patients may enroll with stable, responding or progressive tumor burden

          -  Performance status of 0,1 or 2

        Exclusion Criteria:

          -  Patients unable or unwilling to provide informed consent and or perform study
             procedures

          -  Patients with active, uncontrolled coagulopathy

          -  Patients on treatment dose anticoagulation or an International Normalised Ratio of 2
             or greater if on warfarin

          -  Patients who are known to be pregnant are not eligible to participate in this study
             during the time of the pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Van Poznak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine H Van Poznak, MD</last_name>
      <email>cvanpoz@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Answer Line</last_name>
      <phone>800-865-1125</phone>
      <email>canceranswerline@umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Van Poznak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>September 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
